clinical trial · NCT04375150
Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC
Pfizer·—·completed·n = 355
Renal Cell Carcinoma (RCC)Tyrosine kinase inhibitor (TKI)Immuno-oncology (IO)
brief summary
The study aims to assess treatment patterns and outcomes in advanced RCC patients in real world clinical practices across various real world databases. Four databases will be evaluated
started
Dec 2, 2019
primary completion
Oct 28, 2022
completion
Oct 28, 2022
last updated
Sep 19, 2024
official title
Study of Advanced Renal Cell Carcinoma Treatment Patterns and Unmet Needs Using Real World Claims and Electronic Medical Record Data.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol